Neuromyelitis Optica Spectrum Disorder

WEST PALM BEACH, Fla. — Large language model algorithms may be reliable for synthesizing large patient databases to more rapidly and accurately diagnose multiple sclerosis, according to a poster presented at ACTRIMS.

Among individuals who were prescribed approved biologics for neuromyelitis optica spectrum disorder, those on inebilizumab had significantly higher medication adherence, according to a study presented at ECTRIMS 2024.

In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.

The FDA approved Ultomiris for the treatment of adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, according to a press release from Alexion.

WEST PALM BEACH, Fla. — Hispanic and Latino individuals with neuromyelitis optica spectrum disorder experienced improved outcomes with Uplizna compared with placebo, according to a poster from ACTRIMS 2024.

Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.

Presence of cytokine proteins in those with neuromyelitis optica spectrum disorder was linked to disease activity, which was lessened after treatment with inebilizumab, according to a presentation from ECTRIMS 2023.

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.